生物制剂治疗所致乙型肝炎病毒再激活研究进展

doi:10.3969/j.issn.1672-5069.2023.02.037

摘要/Abstract

摘要： 目的随着生物制剂在临床逐步广泛的应用,由此导致的乙型肝炎病毒(HBV )再激活越来越受关注。HBV再激活的患者可发生肝衰竭,甚至导致死亡。对有HBV再激活发生风险的人群进行筛查、预防性抗病毒治疗和监测, 已经成为各大指南的共识。本文就在应用生物制剂治疗过程中HBV再激活的发生风险分层、发生机制和预防性抗病毒治疗药物应用等作一综述。

关键词: 乙型肝炎病毒, 生物制剂, 再激活

Abstract: Objective With the wide application of biologics, the hepatitis B virus (HBV) reactivation have been increasingly become a problem. The patients with HBV reactivation may suffer from liver failure, which might lead to death. The screening, prophylactic antiviral therapy and surveillance for the patients at a risk of HBV reactivation have become the consensus of major related guidelines. In this article, we reviewed the population risk stratification, mechanism by which the HBV reactivated, and the prophylactic antiviral agents.

Key words: Hepatitis B virus, Biologics, Reactivation

李杨洲, 陆爽. 生物制剂治疗所致乙型肝炎病毒再激活研究进展[J]. 实用肝脏病杂志, 2023, 26(2): 297-300.

Li Yangzhou, Lu Shuang. Hepatitis B virus reactivation during biologics therapy[J]. Journal of Practical Hepatology, 2023, 26(2): 297-300.

参考文献

[1] Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol, 2019, 4(7): 545-558.
[2] Lok AS, Zoulim F, Dusheiko G, et al. Hepatitis B cure: From discovery to regulatory approval. Hepatology, 2017, 66(4): 1296-1313.
[3] B Werle-Lapostolle, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology, 2004, 126(7): 1750-1758.
[4] Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol, 2014, 11(4): 209-219.
[5] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67(4): 1560-1599.
[6] 王贵强, 段钟平, 王福生, 等. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 22(1): 9-32.
[7] Pauly MP, Tucker LY, Szpakowski JL, et al. Incidence ofhepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. Clin Gastroenterol Hepatol, 2018, 16(12): 1964-1973.
[8] MM Mücke, Backus L I, VT Mücke, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2018, 3(3): 172-180.
[9] Yu S, Jianqin H, Wei W, et al. The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis. Ann Hepatol, 2013, 12(3): 364-372.
[10] Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology, 2011, 53(3): 774-780.
[11] Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science, 2014, 343(6176): 1221-1228.
[12] Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellularinactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity, 1996, 4(1): 25-36.
[13] Cantini F, Boccia S, Goletti D, et al. HBVreactivation in patients treated with antitumor necrosis factor-alpha (TNF-α) agents for rheumatic and dermatologic donditions: A systematic review and Meta-analysis. Int J Rheumatol, 2014, 2014: 926836.
[14] Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol, 2011, 22(5): 1170-1180.
[15] Seto WK, Chan T, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol, 2014, 32(33): 3736-3743.
[16] Vincenti F, Rostaing L, Grinyo J, et al. Belatacept andlong-term outcomes in kidney transplantation REPLY. N Engl J Med, 2016, 374: 333-343.
[17] Blair HA, Deeks ED. Abatacept: A review in rheumatoid arthritis. Drugs, 2017, 77(11): 1221-1233.
[18] Kim PS, Ho GY, Prete PE, et al. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken), 2012, 64(8): 1265-1268.
[19] Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol, 2018, 53: 49-63.
[20] Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol, 2013, 169(6): 1295-1303.
[21] Chiu HY, Hui CY, Huang YH, et al. Safetyproﬁle of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: A multicentric prospective cohort study. Acta Derm Venereol, 2018, 98(9): 829-834.
[22] Palomo J, Dietrich D, Martin P, et al. The interleukin (IL)-1 cytokine family - Balance between agonists and antagonists in inflammatory diseases. Cytokine, 2015, 76(1): 25-37.
[23] Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol, 2015, 16(5): 448-457.
[24] Nakamura J, Nagashima T, Nagatani K, et al. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis, 2016, 19(5): 470-475.
[25] Fisicaro P, Valdatta C, Massari M, et al. Combinedblockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, But Not HCV. Gastroenterology, 2012, 143(6): 1576-1585.
[26] Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol, 2019, 71(5): 900-907.
[27] Yao ZH, Liao WY, Ho CC, et al. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. Eur J Cancer, 2019, 117: 107-115.
[28] Ferrari SM, Bocci G, Di Desidero T, et al. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol Rep, 2018, 39(5): 2225-2234.
[29] Waldmann TA, Chen J. Disorders of the JAK/STATpathway in T cell lymphoma pathogenesis: Implications for immunotherapy. Annu Rev Immunol, 2017, 35(1): 533-550.
[30] Janssen, Harry, Agarwal, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, European Association for the Study of the Liver. J Hepatol, 2017, 67(2): 370-398.
[31] Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et al. Hepatitis Bvirus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: Analysis of 257 cases. Medicine (Baltimore), 2011, 90(6): 359-371.
[32] Cainelli F, Longhi MS, Concia E, et al. Failure of lamivudine therapy for chemotherapy-induced reactivation ofhepatitis B. Am J Gastroenterol, 2001, 96(5): 1651-1652.
[33] Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol, 2017, 11(11): 999-1008.
[34] Chang CS, Tsai CY, Yan SL, et al. Hepatitis B reactivation in patients receiving targeted therapies. Hematology, 2017, 22(10): 592-598.